特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の前立腺がん治療薬市場:医薬品の種類別、流通チャネル別-市場機会の分析と業界予測(2019年~2026年)

Prostate Cancer Treatment Market by Drug Type and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019-2026

発行 Allied Market Research 商品コード 927307
出版日 ページ情報 英文 188 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
世界の前立腺がん治療薬市場:医薬品の種類別、流通チャネル別-市場機会の分析と業界予測(2019年~2026年) Prostate Cancer Treatment Market by Drug Type and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日: 2020年01月01日 ページ情報: 英文 188 Pages
概要

前立腺がんは、男性の生殖器系で発生するがんの一種で、無症候性であり、初期段階では進行も早くありませんが、男性では皮膚がんに次いで2番目に多いがんです。前立腺がんの治療には、初期段階では放射線療法、腫瘍が前立腺を越えて広がった段階では薬物療法が推奨され、薬物療法には、化学療法、生物学的療法、ホルモン療法が含まれます。前立腺がん治療薬の市場は、有病率の大幅な増加、高齢者人口の増加、前立腺癌の治療に関する人々の意識の高まりなどに伴って急速に成長しており、世界の市場規模は、2018年の時点で68億8,700万ドル、2026年には99億400万ドルに拡大する見通しであり、2019年から2026年までのCAGRは4.6%になります。

当レポートは、世界の前立腺がん治療薬市場を調査したもので、市場の概要、治療薬の種類別、流通チャネル別、地域別の分析、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

  • レポートの概要
  • 利害関係者の主な利点
  • 主要市場セグメント
    • 主要企業のリスト
  • 調査手法
    • 二次次調査
    • 一次調査
    • アナリストのツールとモデル

第2章 エグゼクティブサマリー

  • 主要な調査結果
  • Cxoの見解

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資銘柄
    • 主要企業の立ち位置 (2018年)
  • ポーターのファイブフォース分析
  • 市場力学
    • 成長促進要因
    • 成長阻害要因
    • 市場機会
    • 影響分析

第4章 市場分析:医薬品の種類別

  • 概要
    • 市場規模と予測
  • ホルモン療法
    • 市場の主なトレンド、成長要因、機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 生物学的療法
  • 化学療法
  • その他

第5章 市場分析:流通チャネル別

  • 概要
    • 市場規模と予測
  • 病院内の薬局
  • ドラッグストアと小売薬局
  • オンライン薬局

第6章 市場分析:地域別

  • 概要
    • 市場規模と予測
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ

第7章 企業プロファイル

  • アステラス製薬
  • Astrazeneca Plc
  • Bayer Ag.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ag
  • Ferring Pharmaceuticals Inc.
  • Glaxosmithkline Plc.
  • Ipsen Pharma
  • Johnson & Johnson
  • 武田薬品工業
図表

List of Tables

  • Table 01. Global Prostate Cancer Treatment Market, By Drug Type, 2018-2026 ($Million)
  • Table 02. Hormone Therapy Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 03. Biological Therapy Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 04. Chemotherapy Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 05. Others Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 06. Global Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026 ($Million)
  • Table 07. Hospital Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 08. Drug Stores & Retail Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 09. Online Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 10. Prostate Cancer Treatment Market, By Region, 2018-2026 ($Million)
  • Table 11. North America Prostate Cancer Treatment Market, By Country, 2018-2026 ($Million)
  • Table 12. U.S. Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 13. U.S. Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 14. Canada Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 15. Canada Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 16. Mexico Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 17. Mexico Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 18. North America Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 19. North America Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 20. Europe Prostate Cancer Treatment Market, By Country, 2018-2026 ($Million)
  • Table 21. Germany Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 22. Germany Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 23. France Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 24. France Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 25. Uk Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 26. Uk Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 27. Italy Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 28. Italy Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 29. Spain Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 30. Spain Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 31. Rest of Europe Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 32. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 33. Europe Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 34. Europe Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 35. Asia-Pacific Prostate Cancer Treatment Market, By Country, 2018-2026 ($Million)
  • Table 36. Japan Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 37. Japan Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 38. China Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 39. China Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 40. Australia Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 41. Australia Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 42. India Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 43. India Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 44. South Korea Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 45. South Korea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 46. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 47. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 48. Asia-Pacific Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 49. Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 50. Lamea Prostate Cancer Treatment Market, By Country, 2018-2026 ($Million)
  • Table 51. Brazil Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 52. Brazil Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 53. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 54. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 55. South Africa Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 56. South Africa Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 57. Rest of Lamea Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 58. Rest of Lamea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 59. Lamea Prostate Cancer Treatment Market, By Drug Type, 2018-2026
  • Table 60. Lamea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026
  • Table 61. Astellas: Company Snapshot
  • Table 62. Astellas: Product Portfolio
  • Table 63. Astrazeneca: Company Snapshot
  • Table 64. Astrazeneca: Operating Business Segments
  • Table 65. Astrazeneca: Product Portfolio
  • Table 66. Bayer.: Company Snapshot
  • Table 67. Bayer.: Operating Segments
  • Table 68. Bayer.: Product Portfolio
  • Table 69. Bms: Company Snapshot
  • Table 70. Bms: Product Portfolio
  • Table 71. Roche: Company Snapshot
  • Table 72. Roche: Operating Segments
  • Table 73. Roche: Product Portfolio
  • Table 74. Ferring: Company Snapshot
  • Table 75. Ferring: Product Business Segment
  • Table 76. Ferring: Product Portfolio
  • Table 77. Gsk.: Company Snapshot
  • Table 78. Gsk.: Operating Business Segments
  • Table 79. Gsk.: Product Portfolio
  • Table 80. Ipsen: Company Snapshot
  • Table 81. Ipsen: Operating Segments
  • Table 82. Ipsen: Product Portfolio
  • Table 83. J&J: Company Snapshot
  • Table 84. J&J: Operating Business Segments
  • Table 85. J&J: Product Portfolio
  • Table 86. Takeda: Company Snapshot
  • Table 87. Takeda: Product Portfolio

List of Figures

  • Figure 01. Global Prostate Cancer Treatment Market Segmentation
  • Figure 02. Top Investment Pockets
  • Figure 03. Market Player Positioning, 2018
  • Figure 04. High Bargaining Power of Suppliers
  • Figure 05. Moderate Bargaining Power of Buyers
  • Figure 06. Moderate Threat of Substitutes
  • Figure 07. Moderate Threat of New Entrants
  • Figure 08. High Intensity of Rivalry
  • Figure 09. Impact Analysis
  • Figure 10. Comparative Analysis of Hormone Therapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 11. Comparative Analysis of Biological Therapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 12. Comparative Analysis of Chemotherapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 13. Comparative Analysis of Others Prostate Cancer Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 14. Comparative Analysis of Hospital Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 15. Comparative Analysis Drug Stores & Retail Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (%)
  • Figure 16. Comparative Analysis of Online Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (%)
  • Figure 17. Astellas: Net Sales, 2016-2018 ($Million)
  • Figure 18. Astellas: Revenue Share By Segment, 2018 (%)
  • Figure 19. Astellas: Revenue Share By Region, 2018 (%)
  • Figure 20. Astrazeneca: Net Sales, 2016-2018 ($Million)
  • Figure 21. Astrazeneca: Revenue Share By Region, 2018(%)
  • Figure 22. Bayer: Net Sales, 2016-2018 ($Million)
  • Figure 23. Bayer: Revenue Share By Segment, 2018 (%)
  • Figure 24. Bayer: Revenue Share By Region, 2018(%)
  • Figure 25. Bms: Net Sales, 2016-2018 ($Million)
  • Figure 26. Bms: Revenue Share By Region, 2018 (%)
  • Figure 27. Roche: Net Sales, 2016-2018 ($Million)
  • Figure 28. Roche: Revenue Share By Segment, 2018 (%)
  • Figure 29. Roche: Revenue Share By Region, 2018 (%)
  • Figure 30. Ferring: Net Sales, 2016-2018 ($Million)
  • Figure 31. Ferring: Revenue Share By Segment, 2018(%)
  • Figure 32. Ferring: Revenue Share By Region, 2018(%)
  • Figure 33. Gsk: Net Sales, 2016-2018 ($Million)
  • Figure 34. Gsk: Revenue Share By Segment, 2018 (%)
  • Figure 35. Gsk: Revenue Share By Region, 2018(%)
  • Figure 36. Ipsen: Net Sales, 2016-2018 ($Million)
  • Figure 37. Ipsen: Revenue Share By Segments, 2018(%)
  • Figure 38. Ipsen: Revenue Share By Region, 2018(%)
  • Figure 39. J&J: Net Sales, 2016-2018 ($Million)
  • Figure 40. J&J: Revenue Share By Segment, 2018 (%)
  • Figure 41. J&J: Revenue Share By Region, 2018(%)
  • Figure 42. Takeda: Net Sales, 2016-2018 ($Million)
  • Figure 43. Takeda: Revenue Share By Region, 2018 (%)
目次
Product Code: LI_182653

The global prostate cancer treatment market was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Prostate cancer is a type of cancer that develops in the male reproductive system. It is asymptomatic, and grow slowly at its earliest stages. Furthermore, it is the second most common cancer in male after skin cancer. In case of treatment, the initial stage of prostate cancer are treated by radiation therapy, and for the last stages, where tumor has spread beyond the prostate gland, drug therapies are recommended. The drug therapies include chemotherapy, biological therapy, and hormone therapy. Xtandi and Zytiga are the major therapeutic drugs that are used for the treatment of prostate cancer.

Significant increase in prevalence of prostate cancer, rise in geriatric population, surge in awareness among people regarding the treatment of prostate cancer, increase in demand for prostate cancer treatment products, and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings are the key factors that fuel the growth of the prostate cancer treatment market. Moreover, availability of new prostate cancer treatments, strong emerging pipeline drugs, improved R&D investment by drug innovators, enhanced diagnosis & incidence rates in developed economies, increase in generic products, and rise in pharmaceutical industries & diagnostic centers across the globe contribute toward the growth of the market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to hinder the growth of the market.

The prostate cancer treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, the market is categorized into chemotherapy, biological therapy, hormone therapy, and others. Depending on distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Type

  • Chemotherapy
  • Biological Therapy
  • Hormone Therapy
  • Others

By Distribution Channel

  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Ltd
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Tolmar Inc.
  • Indevus Pharmaceuticals
  • Sanofi S.A.

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Benefits For Stakeholders
  • 1.3. Key Market Segments
    • 1.3.1. List of Key Players Profiled In The Report
  • 1.4. Research Methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Key Findings of The Study
  • 2.2. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Market Player Positioning, 2018
  • 3.3. Porter'S Five Force Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase In Prevalence of Prostate Cancer
      • 3.4.1.2. Rise In In Geriatric Population
      • 3.4.1.3. Increase In Government Expenditure On Healthcare
    • 3.4.2. Restraint
      • 3.4.2.1. Adverse Effects Associated With The Use Prostate Cancer Treatment Drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth Opportunities In Emerging Markets
    • 3.4.4. Impact Analysis

Chapter 4: Prostate Cancer Treatment Market, By Drug Type

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Hormone Therapy
    • 4.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.2.2. Market Size And Forecast, By Region
    • 4.2.3. Market Analysis, By Country
  • 4.3. Biological Therapy
    • 4.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.3.2. Market Size And Forecast
    • 4.3.3. Market Analysis, By Country
  • 4.4. Chemotherapy
    • 4.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.4.2. Market Size And Forecast
    • 4.4.3. Market Analysis, By Country
  • 4.5. Others
    • 4.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.5.2. Market Size And Forecast
    • 4.5.3. Market Analysis, By Country

Chapter 5: Prostate Cancer Treatment Market, By Distribution Channel

  • 5.1. Overview
    • 5.1.1. Market Size And Forecast
  • 5.2. Hospital Pharmacy
    • 5.2.1. Market Size And Forecast
    • 5.2.2. Market Analysis, By Country
  • 5.3. Drug Stores & Retail Pharmacy
    • 5.3.1. Market Size And Forecast
    • 5.3.2. Market Analysis, By Country
  • 5.4. Online Pharmacy
    • 5.4.1. Market Size And Forecast
    • 5.4.2. Market Analysis, By Country

Chapter 6: Prostate Cancer Treatment Market, By Region

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast
  • 6.2. North America
    • 6.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 6.2.2. Market Size And Forecast, By Country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. Prostate Cancer Treatment Market, By Drug Type
      • 6.2.2.1.2. U.S. Prostate Cancer Treatment Market, By Distribution Channel
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada Prostate Cancer Treatment Market, By Drug Type
      • 6.2.2.2.2. Canada Prostate Cancer Treatment Market, By Distribution Channel
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico Prostate Cancer Treatment Market, By Drug Type
      • 6.2.2.3.2. Mexico Prostate Cancer Treatment Market, By Distribution Channel
    • 6.2.3. North America Market Size And Forecast, By Drug Type
    • 6.2.4. North America Market Size And Forecast, By Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 6.3.2. Market Size And Forecast, By Country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany Prostate Cancer Treatment Market, By Drug Type
      • 6.3.2.1.2. Germany Prostate Cancer Treatment Market, By Distribution Channel
      • 6.3.2.2. France
      • 6.3.2.2.1. France Prostate Cancer Treatment Market, By Drug Type
      • 6.3.2.2.2. France Prostate Cancer Treatment Market, By Distribution Channel
      • 6.3.2.3. Uk
      • 6.3.2.3.1. Uk Prostate Cancer Treatment Market, By Drug Type
      • 6.3.2.3.2. Uk Prostate Cancer Treatment Market, By Distribution Channel
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Italy Prostate Cancer Treatment Market, By Drug Type
      • 6.3.2.4.2. Italy Prostate Cancer Treatment Market, By Distribution Channel
      • 6.3.2.5. Spain
      • 6.3.2.5.1. Spain Prostate Cancer Treatment Market, By Drug Type
      • 6.3.2.5.2. Spain Prostate Cancer Treatment Market, By Distribution Channel
      • 6.3.2.6. Rest of Europe
      • 6.3.2.6.1. Rest of Europe Prostate Cancer Treatment Market, By Drug Type
      • 6.3.2.6.2. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel
    • 6.3.3. Europe Market Size And Forecast, By Drug Type
    • 6.3.4. Europe Market Size And Forecast, By Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 6.4.2. Market Size And Forecast, By Country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan Prostate Cancer Treatment Market, By Drug Type
      • 6.4.2.1.2. Japan Prostate Cancer Treatment Market, By Distribution Channel
      • 6.4.2.2. China
      • 6.4.2.2.1. China Prostate Cancer Treatment Market, By Drug Type
      • 6.4.2.2.2. China Prostate Cancer Treatment Market, By Distribution Channel
      • 6.4.2.3. Australia
      • 6.4.2.3.1. Australia Prostate Cancer Treatment Market, By Drug Type
      • 6.4.2.3.2. Australia Prostate Cancer Treatment Market, By Distribution Channel
      • 6.4.2.4. India
      • 6.4.2.4.1. India Prostate Cancer Treatment Market, By Drug Type
      • 6.4.2.4.2. India Prostate Cancer Treatment Market, By Distribution Channel
      • 6.4.2.5. South Korea
      • 6.4.2.5.1. South Korea Prostate Cancer Treatment Market, By Drug Type
      • 6.4.2.5.2. South Korea Prostate Cancer Treatment Market, By Distribution Channel
      • 6.4.2.6. Rest of Asia-Pacific
      • 6.4.2.6.1. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type
      • 6.4.2.6.2. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel
    • 6.4.3. Asia-Pacific Market Size And Forecast, By Drug Type
    • 6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel
  • 6.5. Lamea
    • 6.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 6.5.2. Market Size And Forecast, By Country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil Prostate Cancer Treatment Market, By Drug Type
      • 6.5.2.1.2. Brazil Prostate Cancer Treatment Market, By Distribution Channel
      • 6.5.2.2. Saudi Arabia
      • 6.5.2.2.1. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type
      • 6.5.2.2.2. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel
      • 6.5.2.3. South Africa
      • 6.5.2.3.1. South Africa Prostate Cancer Treatment Market, By Drug Type
      • 6.5.2.3.2. South Africa Prostate Cancer Treatment Market, By Distribution Channel
      • 6.5.2.4. Rest of Lamea
      • 6.5.2.4.1. Rest of Lamea Prostate Cancer Treatment Market, By Drug Type
      • 6.5.2.4.2. Rest of Lamea Prostate Cancer Treatment Market, By Distribution Channel
    • 6.5.3. Lamea Market Size And Forecast, By Drug Type
    • 6.5.4. Lamea Market Size And Forecast, By Distribution Channel

Chapter 7: Company Profiles

  • 7.1. Astellas Pharma Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Operating Business Segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business Performance
  • 7.2. Astrazeneca Plc
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Operating Business Segments
    • 7.2.4. Product Portfolio
    • 7.2.5. Business Performance
  • 7.3. Bayer Ag.
    • 7.3.1. Company Overview
    • 7.3.2. Operating Business Segments
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Performance
    • 7.3.5. Key Strategic Moves And Developments
  • 7.4. Bristol-Myers Squibb Company
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Operating Business Segments
    • 7.4.4. Product Portfolio
    • 7.4.5. Business Performance
  • 7.5. F. Hoffmann-La Roche Ag
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Operating Business Segments
    • 7.5.4. Product Portfolio
    • 7.5.5. Business Performance
  • 7.6. Ferring Pharmaceuticals Inc.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Operating Business Segments
    • 7.6.4. Product Portfolio
    • 7.6.5. Business Performance
  • 7.7. Glaxosmithkline Plc.
    • 7.7.1. Company Overview
    • 7.7.2. Operating Business Segments
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Performance
  • 7.8. Ipsen Pharma
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Operating Business Segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business Performance
  • 7.9. Johnson & Johnson
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Operating Business Segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business Performance
    • 7.9.6. Key Strategic Moves And Developments: Global
  • 7.10. Takeda Pharmaceutical Company Ltd
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Operating Business Segments
    • 7.10.4. Product Portfolio
    • 7.10.5. Business Performance